Business
Agenus to Host First 2026 Stakeholder Webcast
LEXINGTON, Mass., January 20, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET.
About this update from Agenus Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/90b4c3258f6743f5addd0ddb91d0b4e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FWggIodZcm6v_63lIZCkoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/90b4c3258f6743f5addd0ddb91d0b4e4","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/G7aUfdiQnVF4UpcyaT5A8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/90b4c3258f6743f5addd0ddb91d0b4e4","width":1200,"height":250}},"lazy":false},{"type":"text","content":"Access to Acceleration: Agenus’ BOT+BAL Global Momentum Entering 2026","length":69,"tagName":"p","attribs":{}},{"type":"text","content":"Webcast on Wednesday, January 28, 2026, at 4:00 p.m. ET","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., January 20, 2026--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET.","length":309,"tagName":"p"},{"type":"text","content":"The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus’ botensilimab and balstilimab (BOT+BAL) program entering 2026. The session will feature perspectives from Agenus leadership and a leading international oncology expert on progress across authorized access programs, clinical development, and priorities for the year ahead.","length":418,"tagName":"p"},{"type":"text","content":"The session will be moderated by Garo Armen, PhD, Founder, Chairman, and Chief Executive Officer of Agenus, and will conclude with a live Q&A. Questions can be submitted in advance to [email protected].","length":206,"tagName":"p"},{"type":"text","content":"Featured Topics and Speakers","length":28,"tagName":"p"},{"type":"text","content":"1. From Access to Acceleration: Strengthening the Global Foundation for BOT+BALGaro Armen, PhDFounder, Chairman, and Chief Executive Officer, Agenus","length":150,"tagName":"p","attr...